U.S. Markets close in 1 hr 19 mins
  • S&P 500

    4,407.83
    +6.37 (+0.14%)
     
  • Dow 30

    34,993.56
    -64.96 (-0.19%)
     
  • Nasdaq

    14,768.57
    +107.99 (+0.74%)
     
  • Russell 2000

    2,217.86
    +26.02 (+1.19%)
     
  • Crude Oil

    72.39
    +0.74 (+1.03%)
     
  • Gold

    1,797.30
    -2.50 (-0.14%)
     
  • Silver

    24.89
    +0.24 (+0.96%)
     
  • EUR/USD

    1.1839
    +0.0013 (+0.1066%)
     
  • 10-Yr Bond

    1.2590
    +0.0250 (+2.03%)
     
  • Vix

    18.11
    -1.25 (-6.46%)
     
  • GBP/USD

    1.3900
    +0.0021 (+0.1501%)
     
  • USD/JPY

    110.0010
    +0.2340 (+0.2132%)
     
  • BTC-USD

    39,919.10
    +2,005.46 (+5.29%)
     
  • CMC Crypto 200

    935.20
    +5.28 (+0.57%)
     
  • FTSE 100

    7,016.63
    +20.55 (+0.29%)
     
  • Nikkei 225

    27,581.66
    -388.56 (-1.39%)
     

G1 Therapeutics to Provide Second Quarter 2020 Corporate and Financial Update on August 5, 2020

·1 min read

RESEARCH TRIANGLE PARK, N.C., July 29, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2020 on Wednesday, August 5, 2020 at 5:00 p.m. ET.

The live call may be accessed by dialing 866-763-6020 (domestic) or 210-874-7713 (international) and entering the conference code: 4648036. The live and archived webcast will be available on the Events & Presentations page of the G1 website.

About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. Trilaciclib is a first-in-class FDA-designated Breakthrough Therapy designed to improve outcomes for patients being treated with chemotherapy. Rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. Lerociclib is a differentiated oral CDK4/6 inhibitor designed to enable more effective combination treatment strategies.

G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contact:
Jeff Macdonald
Senior Director, Investor Relations & Corporate Communications
919-907-1944
jmacdonald@g1therapeutics.com